The Foundation 60
What Is Foundation 60™?
Foundation 60™ is a 60-day structured research protocol designed for extended metabolic signaling observation and deeper evaluation of biological response patterns over time.
This protocol combines Retatrutide and MOTS-c, two research compounds studied across complementary metabolic pathways. Retatrutide is investigated for triple-receptor signaling through GLP-1, GIP, and glucagon pathways, while MOTS-c is studied as a mitochondrial-derived peptide involved in cellular energy sensing, AMPK-related signaling, and metabolic adaptation.
Foundation 60™ builds on the same core principle as Foundation 30™ but extends the observation window. This allows researchers to move beyond initial response tracking and into more consistent pattern recognition across metabolic, behavioral, mitochondrial, and systemic signaling domains.
Rather than increasing protocol complexity, Foundation 60™ keeps the stack focused: one systemic metabolic signaling compound paired with one mitochondrial communication peptide.
Certificate of Analysis
Third-party testing documentation available for purity and analytical verification.
Foundation 60™ Research Overview
Foundation 60™ is the extended version of the Foundation Protocol™, created for researchers who want a longer and more stable observation period for metabolic signaling research.
This 60-day protocol includes:
The 60-day structure allows researchers to observe signaling consistency, behavioral patterns, metabolic-response trends, and mitochondrial adaptation over a longer window compared with shorter entry-level protocols.
Why a 60-Day Protocol?
Metabolic signaling and mitochondrial adaptation are not always best understood through short-term observation. Many biological response patterns develop gradually through repeated pathway exposure, consistent tracking, and structured evaluation.
Foundation 60™ was designed to support a longer research window where investigators can observe:
- Signal consistency
- Appetite-related pathway patterns
- Energy-stability trends
- Metabolic-response markers
- Mitochondrial communication models
- Training and recovery-related observations
- Sleep and rhythm-related patterns
- Body-composition trend tracking
The goal of Foundation 60™ is not intensity. The goal is consistency, stability, and structured observation over time.
The Science Behind the Stack
Retatrutide
Retatrutide, also known as LY3437943, is studied as a triple GLP-1, GIP, and glucagon receptor agonist. These receptor systems are associated with incretin biology, glucose regulation, insulin-response pathways, glucagon-related energy signaling, lipid metabolism, appetite-related pathways, and systemic energy balance.
In research settings, triple-agonist compounds are often examined because they allow researchers to study broader metabolic pathway engagement compared with single-receptor or dual-receptor models.
Within Foundation 60™, Retatrutide represents the systemic receptor-signaling component of the protocol.
MOTS-c
MOTS-c is a 16βamino acid mitochondrial-derived peptide encoded within mitochondrial DNA. It is studied for its relationship with cellular energy sensing, AMPK-dependent signaling, glucose metabolism, insulin-sensitivity models, mitochondrial-to-nuclear communication, and adaptive stress-response pathways.
Research models often examine MOTS-c in the context of metabolic flexibility, skeletal-muscle energy signaling, cellular response to nutrient stress, and age-related metabolic adaptation.
Within Foundation 60™, MOTS-c represents the mitochondrial and intracellular energy-communication component of the protocol.
Why These Two Compounds Are Paired
Metabolic regulation operates across multiple biological layers.
Retatrutide is studied for systemic receptor-level signaling through GLP-1, GIP, and glucagon pathways.
MOTS-c is studied for mitochondrial and intracellular energy communication, especially pathways related to AMPK activation, glucose utilization, metabolic flexibility, and stress adaptation.
Together, they create a focused two-layer research framework:
- Systemic metabolic signaling
- Cellular energy responsiveness
Foundation 60™ extends this pairing over a longer duration, allowing researchers to document more stable and observable signaling patterns across a structured 60-day research environment.
Who Foundation 60™ Is Best For
Foundation 60™ may be useful for controlled research models focused on:
- Extended metabolic signaling observation
- Longer-duration mitochondrial communication research
- Researchers progressing from shorter protocol structures
- Structured trend tracking over time
- Lower-complexity protocol design with extended observation
- Metabolic stability and pattern-recognition research
- Receptor-level and intracellular signaling interaction
- Body-composition and energy-balance research models
What Researchers May Document
In controlled research environments, Foundation 60™ may be used in protocols where researchers document broad biological and behavioral patterns over time, including:
- Appetite-pattern consistency
- Energy-stability trends
- Craving-related behavior patterns
- Metabolic-response markers
- Recovery-related observations
- Training-response models
- Body-composition patterns
- Sleep and rhythm-related notes
- Protocol consistency and tolerance observations
- Mitochondrial-response indicators
The goal of Foundation 60™ is not to create the most aggressive protocol. The goal is to create a structured research window where response patterns can be observed with more consistency.
The Purple Standard™
Every vial included in Foundation 60™ is handled according to the Purple Standard™. This includes third-party testing, purity verification, controlled storage conditions, batch tracking, and internal rejection of any lot that does not meet required quality thresholds.
The Purple Standard™ exists to support consistency, documentation, and research confidence across every Purple Protocol™.
Investigational Research Context
Foundation 60™ should be considered an investigational research protocol. Available scientific literature primarily examines Retatrutide and MOTS-c individually or in related research contexts. Findings should not be interpreted as approved therapeutic, clinical, veterinary, or human-use outcomes for this protocol.
This product is supplied for laboratory research only and is not intended for human consumption, clinical use, veterinary use, diagnostic use, or self-experimentation.
Scientific References
View References
Retatrutide Research
- Coskun T. et al. (2022) β LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept.
- Urva S. et al. (2022) β LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b randomized trial.
- Jastreboff A.M. et al. (2023) β Triple-hormone-receptor agonist Retatrutide for obesity.
- Rosenstock J. et al. (2023) β Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, for people with type 2 diabetes.
- Sanyal A.J. et al. (2024) β Triple hormone receptor agonist Retatrutide for metabolic dysfunction-associated steatotic liver disease.
MOTS-c Research
- Lee C. et al. (2015) β The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
- Lee C., Yen K., Cohen P. (2016) β MOTS-c: a novel mitochondrial-derived peptide regulating muscle and fat metabolism.
- Kim K.H. et al. (2018) β The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress.
- Reynolds J.C. et al. (2021) β MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.
- Wan W. et al. (2023) β Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism, and aging.
- Zheng Y. et al. (2023) β MOTS-c: a promising mitochondrial-derived peptide for metabolic and aging-related research.
Need Help?


